BriaCell Therapeutics Corp. (BCTX) shares were trading at $10.61, up 39.06% or $2.98 higher, following news of a sustained complete resolution of a lung metastasis in a metastatic breast cancer patient treated with the company's Bria-OTS personalized immunotherapy in an ongoing Phase 1/2a study.
The response was confirmed at multiple timepoints through 11 months of follow-up and was reported without treatment-limiting toxicities, strengthening confidence in the therapeutic potential of the Bria-OTS platform.
On the announcement day, BCTX opened near the prior session's close, rallied to intraday highs well above $10, and maintained elevated trading levels throughout the session as investor interest spiked around this clinical milestone. The stock trades on the NasdaqGS.
Trading volume was reflecting a strong market reaction to the clinical update.
BCTX's 52-week range spans approximately $3.00 to $98.20, illustrating volatility tied to clinical progress and sector sentiment in biotech and cancer immunotherapy development.
For comments and feedback contact: editorial@rttnews.com
Business News
June 12, 2026 17:14 ET Major central bank action was the focus this week in economic news. The European Central Bank became the first major central bank to move in response to the rising inflationary pressures in the backdrop of the conflict in the Middle East. In North America, the U.S. inflation and trade data as well as Canada’s central bank decision gained attention. The Chinese trade data was the main news in Asia.